SOHM, Inc. Agrees to Licensing for Investigational and Pre-Clinical Studies for Groundbreaking ABBIE Genome Editing Technology for CAR-T Cell Cancer Therapies
SOHM Inc (OTC PINK:SHMN) has announced a significant licensing agreement with an undisclosed drug development partner for its ABBIE genome editing technology focused on CAR-T cell cancer therapies. The company is set to receive $6 million in funding for advancing joint research initiatives.
The collaboration centers on SOHM's proprietary ABBIE (A Binding-based Integrase Enzyme) integration system, which aims to enhance the safe and efficient production of autologous CAR-T cells. The partnership combines SOHM's integration system with microfluidic gene editing capabilities to develop new micro-dosed CAR-T cell therapies for cancer treatment.
According to COO David Aguilar, PhD, this collaboration will position SOHM and its partners as leaders in microfluidic-based gene editing technology, potentially revolutionizing treatments for cancer and other diseases.
SOHM Inc (OTC PINK:SHMN) ha annunciato un importante accordo di licenza con un partner non divulgato nel campo dello sviluppo farmaceutico per la sua tecnologia di editing genomico ABBIE focalizzata sulle terapie CAR-T per il cancro. L'azienda riceverà 6 milioni di dollari di finanziamenti per portare avanti iniziative di ricerca congiunta.
La collaborazione si basa sul sistema proprietario di SOHM, il sistema di integrazione ABBIE (A Binding-based Integrase Enzyme), che punta a migliorare la produzione sicura ed efficiente di cellule CAR-T autologhe. La partnership unisce il sistema di integrazione di SOHM alle capacità di editing genico microfluidico per sviluppare nuove terapie CAR-T a microdosaggio per il trattamento del cancro.
Secondo il COO David Aguilar, PhD, questa collaborazione posizionerà SOHM e i suoi partner come leader nella tecnologia di editing genico basata su microfluidica, con il potenziale di rivoluzionare i trattamenti per il cancro e altre malattie.
SOHM Inc (OTC PINK:SHMN) ha anunciado un importante acuerdo de licencia con un socio de desarrollo farmacéutico no revelado para su tecnología de edición genómica ABBIE centrada en terapias CAR-T contra el cáncer. La compañía recibirá 6 millones de dólares en financiamiento para avanzar en iniciativas de investigación conjunta.
La colaboración se basa en el sistema propietario de SOHM, el sistema de integración ABBIE (A Binding-based Integrase Enzyme), que busca mejorar la producción segura y eficiente de células CAR-T autólogas. La asociación combina el sistema de integración de SOHM con capacidades de edición genética microfluídica para desarrollar nuevas terapias CAR-T microdosificadas para el tratamiento del cáncer.
Según el COO David Aguilar, PhD, esta colaboración posicionará a SOHM y sus socios como líderes en tecnología de edición genética basada en microfluídica, con el potencial de revolucionar los tratamientos para el cáncer y otras enfermedades.
SOHM Inc (OTC PINK:SHMN)는 CAR-T 세포 암 치료에 중점을 둔 ABBIE 유전체 편집 기술에 대해 비공개 신약 개발 파트너와 중요한 라이선스 계약을 체결했다고 발표했습니다. 회사는 공동 연구 추진을 위해 600만 달러의 자금을 받게 됩니다.
이번 협력은 SOHM의 독자적인 ABBIE (A Binding-based Integrase Enzyme) 통합 시스템을 중심으로 하며, 자가 CAR-T 세포의 안전하고 효율적인 생산을 향상시키는 것을 목표로 합니다. 이 파트너십은 SOHM의 통합 시스템과 마이크로플루이딕 유전자 편집 기술을 결합하여 암 치료를 위한 새로운 마이크로 도즈 CAR-T 세포 치료법을 개발합니다.
COO David Aguilar 박사에 따르면 이번 협력은 SOHM과 파트너들을 마이크로플루이딕 기반 유전자 편집 기술 분야의 선두주자로 자리매김하게 하며, 암 및 기타 질병 치료에 혁신을 가져올 가능성이 있다고 합니다.
SOHM Inc (OTC PINK:SHMN) a annoncé un accord de licence important avec un partenaire du développement pharmaceutique non divulgué pour sa technologie d’édition génomique ABBIE axée sur les thérapies CAR-T contre le cancer. L’entreprise recevra 6 millions de dollars de financement pour faire avancer des initiatives de recherche conjointes.
Cette collaboration repose sur le système propriétaire de SOHM, le système d’intégration ABBIE (A Binding-based Integrase Enzyme), qui vise à améliorer la production sûre et efficace de cellules CAR-T autologues. Le partenariat combine le système d’intégration de SOHM avec des capacités d’édition génétique microfluidique pour développer de nouvelles thérapies CAR-T microdosées pour le traitement du cancer.
Selon le COO David Aguilar, PhD, cette collaboration positionnera SOHM et ses partenaires comme des leaders dans la technologie d’édition génétique basée sur la microfluidique, avec le potentiel de révolutionner les traitements contre le cancer et d’autres maladies.
SOHM Inc (OTC PINK:SHMN) hat eine bedeutende Lizenzvereinbarung mit einem nicht genannten Partner aus der Arzneimittelentwicklung für seine ABBIE Genom-Editing-Technologie angekündigt, die sich auf CAR-T-Zell-Krebstherapien konzentriert. Das Unternehmen erhält 6 Millionen US-Dollar an Finanzierung zur Förderung gemeinsamer Forschungsinitiativen.
Die Zusammenarbeit basiert auf SOHMs proprietärem ABBIE (A Binding-based Integrase Enzyme) Integrationssystem, das die sichere und effiziente Herstellung autologer CAR-T-Zellen verbessern soll. Die Partnerschaft kombiniert SOHMs Integrationssystem mit mikrofluidischen Gen-Editing-Fähigkeiten, um neue mikro-dosierte CAR-T-Zelltherapien zur Krebsbehandlung zu entwickeln.
Laut COO David Aguilar, PhD, wird diese Zusammenarbeit SOHM und seine Partner als führend in der mikrofluidikbasierten Gen-Editing-Technologie positionieren und möglicherweise die Behandlung von Krebs und anderen Krankheiten revolutionieren.
- Secured $6 million in potential funding through licensing agreement
- Expansion into CAR-T cell therapy market through strategic partnership
- Proprietary ABBIE technology shows commercial potential through licensing
- Partner remains undisclosed, creating uncertainty
- Funding is pending approval, not guaranteed
- Timeline for clinical implementation not specified
CHINO HILLS, CA / ACCESS Newswire / April 28, 2025 / SOHM, Inc. (OTC PINK:SHMN), a leading pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, proudly announces today its collaboration and licensing agreement with an undisclosed emerging drug development partner. This partnership accentuates SOHM's leadership in gene editing and cell engineering.
David Aguilar, PhD, Chief Operating Officer, stated that this collaborative and licensing project will position SOHM and its partners as leaders in microfluidic-based gene editing technology to develop new micro-dosed CAR-T cell therapies to treat cancers. As part of this alliance, our partners are licensing SOHM's proprietary genome editing ABBIE products and methods. This partnership marks a significant leap forward in developing novel genome editing technologies and CAR-T-based therapies poised to revolutionize treatments for cancer and other diseases.
SOHM, Inc., is set to receive
David Aguilar, PhD, Chief Operating Officer, expressed his enthusiasm for the collaboration: "This partnership represents a pivotal moment in the pursuit of advanced genome editing technologies. By integrating our ABBIE system with microfluidic gene editing capabilities, we can accelerate research and bring innovative, cost-efficient micro-dosed CAR-T treatments to the clinic. Most importantly, our efforts will provide new hope for patients battling cancer."
The proposed project aims to streamline gene editing and CAR-T cell processes, making them more accessible and effective for therapeutic applications. By combining SOHM's proprietary integration system with our partners' cutting-edge technology under the license, the collaborators aspire to set new standards in the fields of CAR-T cell therapy and genome editing, significantly impacting the treatment of various diseases and improving overall patient care.
As advancements in genome editing and delivery systems continue to evolve, SOHM, Inc. and its partners are committed to leading the charge in transforming how genetic disorders, especially cancer, are approached. This collaboration signifies a crucial step towards integrating revolutionary technology into clinical practice, ultimately enhancing the future of biotechnology.
For more information about SOHM Inc. and its groundbreaking work in biotechnology, please visit www.SOHM.com.
About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. SOHM strives to transform the landscape of genome editing and improve the quality of life through scientific discovery.
For further information regarding this announcement or to explore potential collaborations, please contact:
SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: info@sohm.com
Phone: (714) 522-6700
Safe Harbor Statement:
This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
SOURCE: SOHM, Inc
View the original press release on ACCESS Newswire
FAQ
What is the value of SOHM's (SHMN) new licensing agreement for ABBIE technology?
How will SOHM's ABBIE technology be used in cancer treatment?
What is SOHM's (SHMN) ABBIE integration system?
What are the expected benefits of SHMN's new partnership in cancer therapy?
